Markus Weigandt

USPTO Granted Patents = 10 (Patent Applications = 5)

CIPO Patents = 5 (Patent Applications = 4)

EPO Patents = 9 (Patent Applications = 11)

Average Co-Inventor Count = 4.6

ph-index = 1

Forward Citations = 2(Granted Patents)

Company Filing History:

where one patent can have more than one assignee

Years Active: 2015-2023

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11559490 - Pharmaceutical formulation (2023-01-24),

2. 11478459 - Pharmaceutical preparation (2022-10-25),

3. 11058769 - Aqueous pharmaceutical formulation comprising anti-PD-L1 antibody Avelumab (2021-07-13),

4. 10561733 - Process for producing nanoparticles laden with active ingredient (2020-02-18),

5. 10561622 - Preparation of nanoparticles-releasing enteric microparticles (2020-02-18),

6. 10369217 - Antigen-loaded chitosan nanoparticles for immunotherapy (2019-08-06),

7. 10111952 - Silicon dioxide nanoparticles and the use thereof for vaccination (2018-10-30),

8. 9808521 - Silicon dioxide nanoparticles and the use thereof for vaccination (2017-11-07),

9. 9433673 - Silicon dioxide nanoparticles and the use thereof for vaccination (2016-09-06),

10. 8980324 - Silicon dioxide nanoparticles and the use thereof for vaccination (2015-03-17),

Title: The Innovative Contributions of Markus Weigandt

Introduction

Markus Weigandt is a notable inventor based in Mannheim, Germany. He has made significant contributions to the field of pharmaceuticals, holding a total of 10 patents. His work focuses on developing innovative pharmaceutical formulations and preparations that have the potential to improve medical treatments.

Latest Patents

Among his latest patents, one includes a pharmaceutical formulation that features (S)-[2-chloro-4-fluoro-5-(7-morpholin-4-yl-quinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)methanol or a pharmaceutically acceptable salt thereof. Another notable patent is related to a solid pharmaceutical preparation of 3-Fluoro-4-[7-methoxy-3-methyl-8-(1-methyl-1H-pyrazol-4-yl)-2-oxo-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl]-benzonitrile, which includes a method of making the preparation and its medical uses.

Career Highlights

Throughout his career, Markus has worked with prominent companies in the pharmaceutical industry, including Merck Patent GmbH and Pfizer Corporation. His experience in these organizations has allowed him to refine his skills and contribute to groundbreaking innovations in drug development.

Collaborations

Markus has collaborated with several talented individuals in his field, including Andrea Hanefeld and Armin Kuebelbeck. These partnerships have fostered a creative environment that encourages the exchange of ideas and advancements in pharmaceutical research.

Conclusion

Markus Weigandt's contributions to the pharmaceutical industry through his patents and collaborations highlight his role as an influential inventor. His work continues to pave the way for advancements in medical treatments and pharmaceutical formulations.

This text is generated by artificial intelligence and may not be accurate.